Monsanto Sees Tremendous Progress In R&D Pipeline
Roundup RReady2Yield Soybean Project Moves To Pre-Launch Phase, One Step Closer To Commercialization
Monsanto reported on seven specific projects in the research-and-development pipeline that either advanced from one phase to the next or were added to the pipeline. The update also highlighted the company's three High Impact Technology (HIT) projects.
"In the last two years, there has been positive movement in 70 percent of the projects in the pipeline," said Robert T. Fraley, Ph.D., chief technology officer and executive vice president for Monsanto. "Of that advancement, almost half are from additions to the pipeline, reflecting the strength of our discovery engine and our collaborative efforts."
The presentation outlined several key measures of progress including the three HIT projects:
* Roundup RReady2Yield soybeans, the company's next-generation, herbicide-tolerant technology in soybeans, moved to Phase 4. The movement, which was based on results from its 2006 breeding trials, advanced the technology one step closer to commercial launch.
* Vistive III soybeans, designed to have a similar oil profile to olive oil, met the company's target composition profile on three of its genetic events.
* First-generation Drought Tolerant corn continued to demonstrate yield benefits in its third year of field testing.
Fraley's presentation was focused on the combined benefits of biotechnology and breeding, emphasizing the fact that both platforms drive plant science innovation. "As excited as we are about the biotech pipeline, we understand that our success rides on the combination of biotechnology and breeding," Fraley said. "We've put a lot of emphasis on making sure that - before we ever look to biotechnology - we have the best, highest yielding seed possible so farmers can start each season strong."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.